{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T01:22:42Z","timestamp":1778116962374,"version":"3.51.4"},"reference-count":15,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Activation of the adaptive Ire1-XBP1 pathway has been identified in many solid tumors and hematologic malignancies, including multiple myeloma (MM). Here, we report the identification of STF-083010, a novel small-molecule inhibitor of Ire1. STF-083010 inhibited Ire1 endonuclease activity, without affecting its kinase activity, after endoplasmic reticulum stress both in vitro and in vivo. Treatment with STF-083010 showed significant antimyeloma activity in model human MM xenografts. Similarly, STF-083010 was preferentially toxic to freshly isolated human CD138+ MM cells compared with other similarly isolated cell populations. The identification of this novel Ire1 inhibitor supports the hypothesis that the Ire1-XBP1 axis is a promising target for anticancer therapy, especially in the context of MM.<\/jats:p>","DOI":"10.1182\/blood-2010-08-303099","type":"journal-article","created":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T22:01:02Z","timestamp":1289944862000},"page":"1311-1314","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":430,"title":["Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma"],"prefix":"10.1182","volume":"117","author":[{"given":"Ioanna","family":"Papandreou","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas C.","family":"Denko","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Olson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heleen","family":"Van Melckebeke","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ghent University Hospital, Ghent, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Lust","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ghent University Hospital, Ghent, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvin","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of California, San Diego, San Diego, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Solow-Cordero","sequence":"additional","affiliation":[{"name":"Stanford University High-Throughput Bioscience Center, Stanford, CA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna M.","family":"Bouley","sequence":"additional","affiliation":[{"name":"Department of Comparative Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ghent University Hospital, Ghent, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Niwa","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of California, San Diego, San Diego, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert C.","family":"Koong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"9686","key":"2019111806493350100_B1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma.","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"2019111806493350100_B2","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2006-11-053728","article-title":"Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells.","volume":"110","author":"Davenport","year":"2007","journal-title":"Blood"},{"issue":"17","key":"2019111806493350100_B3","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1073\/pnas.1334037100","article-title":"Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.","volume":"100","author":"Lee","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2019111806493350100_B4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcadek) in the treatment of multiple myeloma.","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"2019111806493350100_B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0076-6879(01)42530-4","article-title":"Purification and activity assays of the catalytic domains of the kinase\/endoribonuclease Ire1p from Saccharomyces cerevisiae.","volume":"342","author":"Nock","year":"2001","journal-title":"Methods Enzymol"},{"issue":"3","key":"2019111806493350100_B6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1017\/S1355838201002230","article-title":"Basis for regulated RNA cleavage by functional analysis of RNase L and Ire1p.","volume":"7","author":"Dong","year":"2001","journal-title":"RNA"},{"issue":"12","key":"2019111806493350100_B7","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1101\/gad.12.12.1812","article-title":"A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase\/endoribonuclease (Ire1p) in mammalian cells.","volume":"12","author":"Tirasophon","year":"1998","journal-title":"Genes Dev"},{"issue":"7230","key":"2019111806493350100_B8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nature07661","article-title":"The unfolded protein response signals through high-order assembly of Ire1.","volume":"457","author":"Korennykh","year":"2009","journal-title":"Nature"},{"issue":"3","key":"2019111806493350100_B9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.cell.2009.07.017","article-title":"IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates.","volume":"138","author":"Han","year":"2009","journal-title":"Cell"},{"issue":"5650","key":"2019111806493350100_B10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1126\/science.1090031","article-title":"Bypassing a kinase activity with an ATP-competitive drug.","volume":"302","author":"Papa","year":"2003","journal-title":"Science"},{"issue":"1","key":"2019111806493350100_B11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cell.2007.10.057","article-title":"Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing.","volume":"132","author":"Lee","year":"2008","journal-title":"Cell"},{"issue":"2","key":"2019111806493350100_B12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.molcel.2010.04.001","article-title":"Flavonol activation defines an unanticipated ligand-binding site in the kinase-RNase domain of Ire1.","volume":"38","author":"Wiseman","year":"2010","journal-title":"Mol Cell"},{"issue":"7","key":"2019111806493350100_B13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0092-8674(00)81667-0","article-title":"A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response.","volume":"99","author":"Niwa","year":"1999","journal-title":"Cell"},{"issue":"1","key":"2019111806493350100_B14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/0008-5472.CAN-09-2747","article-title":"Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth.","volume":"70","author":"Spiotto","year":"2010","journal-title":"Cancer Res"},{"issue":"17","key":"2019111806493350100_B15","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1158\/0008-5472.CAN-04-1606","article-title":"XBP1 is essential for survival under hypoxic conditions and is required for tumor growth.","volume":"64","author":"Romero-Ramirez","year":"2004","journal-title":"Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/4\/1311\/1341045\/zh800411001311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/4\/1311\/1341045\/zh800411001311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T06:50:45Z","timestamp":1574059845000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/117\/4\/1311\/28562\/Identification-of-an-Ire1alpha-endonuclease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,27]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,1,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2010-08-303099","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,27]]}}}